David Shoultz:
Welcome. We’re here at the International Working Group on MDS and MPN in Washington, D.C. I’m David Schultz. I’m the Chief Scientific Officer at the MPN Research Foundation, and I’m joined by our CEO, Kapila Vig, as well as two of our colleagues and principal investigators for the MPN Progression Registry, Dr. Douglas Tremblay, who is on faculty at the Icahn School of Medicine at Mount Sinai, and Dr. Rajit Rampal from Memorial Sloan Kettering Cancer Center. Welcome to all of you. Thank you. We wanted to take some time this afternoon to actually talk about the MPN Progression Registry, which was launched by the MPN Research Foundation and our team of principal investigators a year ago in September of 2025. To date, we’ve been able to enroll more than 730 patients with MPNs, including those with ET, PV, myelofibrosis. And while we don’t have any currently enrolled patients, we do have eligibility for those with MPN/MDS overlap, as well as MPN accelerated phase or blast phase. Kapila, I wanted to ask you to just share a little bit about the history and the original vision for the MPN Progression Registry? Because obviously, while we launched this last year, I know that it was many, many years in the making.
Kapila Viges:
Yeah. Yeah, it’s a great question. And so MPN Research Foundation, though our primary mission is around research and pursuing novel treatments for MPNs, everything that we do starts and ends with the voice of the patient. So about six or seven years ago, we held a patient-focused drug development meeting and polled 300 patients about what their top concerns are with their MPNs and repeatedly the theme of the uncertainty of progression, understanding whether a patient will progress and what their risk is, how they make their life choices based on living with this for decades, not knowing how they might progress. That springs top of mind for patients again and again and again and again. And so from that was born the Progression Research Network, launched again by the MPN Research Foundation in 2020, with our medical and scientific colleagues to really start to get our arms around how do we start to address this question of who might progress and when and how. And that’s when we turned to our physician scientist colleagues to say, what is it we really need to do to answer some of these really important questions? So while everything starts and ends with the questions and unmet needs of the patients, we quickly turn to what does the field need to be able to answer these questions. And it became very clear that, first of all, we need a better definition of progression. You know, we certainly have very clear diagnostic indicators and certainly things progress to AML. But in between there, what are we really talking about? What are we really looking for? Patients asking, what should I be looking for to know throughout my couple of decades of what it is? So first of all, needing a definition of it. But then it very quickly came, again, from the physician scientists that we really need a little bit more data. We need to be able to look backwards to the natural history of the disease as well as start to look at patients moving data going forward. Because in MPNs that are so variable or heterogeneous, as we say, you know, a lot of the data sets that we have don’t have a lot of, you know, enough power to be able to answer some of these questions. So it became very clear that we needed a much larger data set across the spectrum of MPNs, so including ET, PV, MF, and the adjacent indications as well. But we needed to be able to follow them for much longer periods of time than the current data sets were able to do. And it became very natural that, you know, for us as positioned at MPN Research Foundation, sitting at the intersection of patients, research, and the biopharmaceutical industry, we were perfectly positioned to address some of these sort of fragmentation, data collection, and patient engagement questions in a unique way. And so that was the journey we started four or five years ago with you all to figure out how do we do this? And it’s certainly an aspirational vision that we have to be able to, you know, collect thousands of patient data over many, many years of time. But we thought, you know, we’ve got to start somewhere. And if not us, then who? And so, again, that’s how the MPN Progression Registry was born out of a couple of meetings with our global thought leaders at the Progression Research Network Summit.
David Shoultz:
Thank you. I always love hearing the history because it reminds me of how many years and how many people it actually takes to actually make something like this happen and how many perspectives. And you talked about, you know, obviously our physician scientist colleagues, our patients and caregivers, as well as the biopharmaceutical industry. Rajit, I feel especially lucky to get to work with you closely as PI and our medical advisor at the MPN Research Foundation. You and a number of colleagues, including many who are actually here at this meeting this week, actually earlier this year in the journal Leukemia, actually published an article that also was an outgrowth of this progression research network and was the work of many years, where you actually really focused on disease progression and MPNs as an example and kind of an analogy to precision medicine approaches that we’ve seen in other areas of blood cancers and oncology. And you really focused in on biomarkers. And I wonder how you see the overlap between the enterprise of, you know, what you summarize in the progression manuscript, as we call it, with the work that we’re doing through the MPN progression registry?
Raajit Rampal:
It’s a great question, right? I think that, you know, the problem, as Kapila has laid out, right, is that we don’t have long-term data, we don’t have large numbers, and a lot of these data are siloed in academic institutions. But what the brilliant part of the progression registry is it goes direct to the patient, right? Because there are thousands of patients in the U.S. being cared for every day. There’s data in real time. So that’s, you know, I think where the registry is going to help us. But then the second question becomes, okay, well, if you have all this data, what are you going to do with it? And that’s where the paper comes in, right? We wanted to build a framework for understanding what are the questions that we are actually trying to ask, right? Because it is one thing to ask about, you know, lifespan or disease progression. These things are not always easily captured, but are there other things that we can think about? You mentioned biomarkers, right? Are there routine lab tests that can become surrogate biomarkers of progression? I.e., these are things that are readily discoverable without having to do expensive tests that are not accessible to most patients being taken care of. So it’s really, I think, it interesting having been part of this now for many years to see how it has evolved, but it is really growing from two different perspectives. One is let’s create a structure to capture the data, but then also let’s think about what are we going to do with this and what is it going to mean?
David Shoultz:
Excellent points. And of course, as we’ve been talking about here at the International Working Group meetings, and Doug, as you were talking about earlier, you know, a critically important part of this is actually reflecting the patient voice and the patient experience, whether that patient is one who has myelofibrosis or PV or ET or perhaps something even like MDS-MPN overlap syndrome. You know, we know that there is a lot of variation between MPN types in terms of what patients experience, but then also, as Kapila was saying, a lot of heterogeneity. Even within two or three patients that have ET, you may have very different symptom profiles, very different experiences in terms of what it’s like living with that day-to-day. How do you think about the importance of being able to capture some of that in the registry as a complement to data sources and indices that we already have available to us?
Douglas Tremblay:
David, I think it’s one of the most key components of this registry in comparison to other ones is that this is something that allows patients’ voice to be heard through the registry and collects data that is important on patient-reported outcomes, which are so key across the entire MPN spectrum and through the life of an MPN patient. But I think more fundamentally, what is extremely important is that many times getting diagnosed with an MPN, which is a rare disease, can feel very hopeless. And it is amazing that there is an outlet. I frequently see patients that ask me, what can I do? And many of my patients don’t have the resources to donate money and things like this, but allowing a patient to participate in the research that is going on to contribute an understanding of this disease and how to prevent it and how to prevent progression from occurring, I think is extremely empowering for patients. And it is really an amazing component of the progression network and the registry is giving patients that platform to allow them to participate in advancing the care for the disease.
David Shoultz:
Yeah, I couldn’t agree more. Of course, we ask patients to submit some basic demographic information, of course, to go through an informed consent process. And then once they’re actually enrolled in the registry to allow us to have safe and secure access to their electronic medical record. But then very importantly, at the time of enrollment and every three months, we also ask patients to be doing a short set of patient reported outcomes or PROs that are validated instruments. And I have been very impressed at the rate of participation by enrolled patients in those patient-reported outcomes survey, which, you know, they come every three months. It’s something to do. It only takes you 15 or 20 minutes, but it’s still one more thing to do on a busy day. And I’ve been really impressed that we have, you know, 50, 60, 70, 80 percent of patients actually participating in those. And I do think that a part of it is that people really do want to say, this is my experience, more so than just once a year when I may be asked to fill out an MPN symptom assessment form or whatnot. I also wanted to say that we’ve heard from patients as we’ve been moving along, you know, in our journey with the registry, that they really do want a way to be involved. And so one of the things that we’ve launched is what we’re calling our MPN progression registry meetups, where periodically we actually bring interested patients together virtually. And instead of us just sort of updating them or talking at them or whatnot, we’re actually creating a forum where we can have breakout sessions and where patients can actually lead some of these discussions with other patients who are in the registry. And I was really impressed. We’re doing our first one next Monday, October 5th. And I think we currently have more than 100 patients who have signed up to attend. And many of those have raised their hand and said, I’m happy to lead a breakout discussion or whatnot. That tells me a lot about what you were saying. Are there any other, you know, beyond the capturing the patient voice, are there other things that you’re especially looking forward to, you know, as we think about the abstracts that we’ve submitted to the MPN Congress or the annual ASH meeting this year, are there any other sort of early findings that you’re particularly interested in as a physician scientist?
Douglas Tremblay:
I think two things come to mind when listening to this question. One is what Raajit had alluded to, is that we in academic centers see a snapshot of patients, but we know most patients are treated outside of an academic center. And understanding the patient experience from that standpoint, their symptomatology, their treatments, will allow us to get a much wider breadth of information that can be used to ask really interesting research questions. I think eventually the data being enriched and involved in what Kapila was mentioning with the amazing follow-up time that we’ll be able to have will allow us as researchers to ask questions that can only really be answered in a retrospective study because of how long it takes to develop something like progression, that being able to identify things that may predict for that will also accelerate avenues of research like drug development where we want to halt disease progression and delay that by identifying these endpoints that can be measured earlier on that may be a surrogate for disease progression or other outcomes in the future. So I think there’s a lot of rich information that can be gleaned from the registry that will ultimately translate into real differences for patients and I treating patients in the clinic. Right.
David Shoultz:
And so speaking of that sort of retrospective look backwards at data, if you will, we’re really excited that on average, when we do have patients who are connecting their electronic medical record or EMR, on average, we’re able to see 12, 13, 14 years of data, in many cases, even before the time of that first MPN diagnosis. And we think that’s really powerful when we think about progression. As we begin to wrap up, Raajit, I wanted to ask you to talk a little bit about the future of the MPN progression registry. We have, you know, 730 patients enrolled now. Obviously, we look forward to and are working towards a time when we have 3,000 or 4,000 or 5,000 patients enrolled in the registry. But how else do you think about the future opportunities for the registry?
Raajit Rampal:
In many ways, I think the registry becomes sort of an adaptive platform, meaning that the patients are engaging, as you said. There’s now hundreds of patients involved. There will be probably many, many more coming on. But now the question becomes, what else can we learn? Aside from simple data that’s in the chart, can we begin to capture more data that can be used, for example, for machine learning purposes? Can we actually begin to collect biospecimens and do some more interrogative type science on these samples? I think these are kind of the orthogonal pieces that we want to build onto the platform, which I think will greatly enrich what we learn, but also what we can use for trial endpoints and other uses.
David Shoultz:
Fantastic. Kapila, I know that this has been the work of many years and also the work of probably now thousands of people as well. It really does require, obviously, a tremendous number of resources from the MPN Research Foundation, from our colleagues who are investigators at academic centers. Also, of course, our colleagues who are community hematologists, oncologists who are encouraging their patients to enroll as well. Obviously, our patients and caregivers and advisors. But this also includes our biopharmaceutical partners. And I wondered if you wanted to just maybe close in saying a little bit about their role and how important some of our foundational partners have been.
Kapila Viges:
Yeah, no, it’s a great question because, again, at MPN Research Foundation, we have this opportunity, a very unique one sitting at that intersection where we start with the voice of the patient saying, we have these questions about, will I progress? When? How will my doctor know? We have our scientific colleagues saying, if we could get a little more data over longer periods of time. At the same time, we have our biopharmaceutical colleagues that we sit at the intersection of all three of these voices saying, well, not only are we interested in these insights and all this data is fragmented, we want to know how our development programs are going to be able to help slow, stop, reverse progression and have that meaningful benefit for patients because they truly want to develop their therapeutics in that way. And so, you know, they were part of the making of this whole endeavor. And we’re incredibly grateful because it’s, you know, these do require a lot of resources. We’re incredibly grateful, first and foremost, to Sobi Therapeutics, who saw the vision, asked for a seat at the table with us and really helped us launch and get this off the ground with their intellectual capital by helping guide and share their experiences and certainly with some financial support as well. And very quickly thereafter, GSK was a founding supporter as well as Karyopharm. And so we’re really grateful to them. And since then, we’ve had a handful of others join, including PharmaEssentia, as well as Calithera Biosciences. And so I think one of the interesting things about having this portfolio of biopharmaceutical companies at the table is, one, we’re grateful for the trust that they’re putting in us as a foundation to be able to build something this aspirational and sophisticated that will have application for them in the future. But it’s also an interesting portfolio of companies at very different stages of their drug development and programs, some well-established like GSK and some very early like Calithera Biosciences. And so I think what it really speaks to in the MPN landscape is the commitment from these partners alongside with our physician scientists to really come to the table to the benefit of patients and develop programs that are going to have that meaningful benefit. So really grateful to the biopharmaceutical industry and looking forward to where their support and their guidance takes us alongside our physician scientists.
David Shoultz:
Fantastic. Well, I want to thank all of you for making time to sit down. It’s been a really busy but wonderful several days here in Washington, D.C. I also want to thank Vijay Hemank for giving us the opportunity to talk about the MPN Progression Registry in this forum and wanted to mention that the MPN Progression Registry is certainly open for enrollment. We invite patients, health care providers, and others who would like to learn more to visit our website at mpnresearchfoundation.org or to email us at research@mpnrf.org. Thank you.